|
|
|
| Value of CT combined with serum CEA and ADAM8 in the diagnosis of lung cancer in elderly patients |
| HUANG Linhui HUANG Yijiang▲ |
| Department of Respiratory and Critical Medical, Hainan Provincial People′s Hospital, Hainan Province, Haikou 570311, China |
|
|
|
Abstract Objective To evaluate the value of spiral CT combined with serum carcinoembryonic antigen (CEA) and a disintegrin and metalloprotease 8 (ADAM8) in the clinical diagnosis of elderly patients with lung cancer. Methods A total of 72 elderly patients with lung cancer admitted in Hainan Provincial People′s Hospital (for short “our hospital”) from January to December in 2016 were selected as the study group, and 40 patients with benign pulmonary disease and 40 healthy subjects in our hospital were selected as the control in the same period. All the researchers were underwent CT scan and the serum CEA and ADAM8 were measured. The histopathological results were as the gold standard, the value of single and combined detection indexes for the diagnosis of lung cancer were determined. Results The levels of serum CEA and ADAM8 in lung cancer patients were significantly higher than those in benign lung disease group and healthy control group (P < 0.05); and the levels of CEA and ADAM8 in lung cancer patients with stage Ⅲ/Ⅳ were significantly higher than those in patients with stage Ⅰ/Ⅱ (P < 0.05). The sensitivity of CT, CEA and ADAM8 was 68.06%, 48.61% and 70.83% respectively, the specificity was 90.00%, 75.00% and 86.25% respectively, and the accuracy was 79.61%, 62.50% and 78.95% respectively. The sensitivity, specificity and accuracy of three indicators combined detection were 83.33%, 93.75% and 88.82% respectively, which were higher than single detection. Conclusion CEA has a low detection rate of lung cancer patients and is prone to false positive, but it can improve the accuracy of lung cancer detection after combined with CT and ADAM8.
|
|
|
|
|
|
[1] 李敬华，王萍玉.MicroRNA及SNP在非小细胞肺癌易感性和早期诊断中的作用研究进展[J].中国肿瘤生物治疗杂志，2016，23（3）：446-451.
[2] 王会中，任成山，金发光.肿瘤生物标志物在肺癌患者检测中的临床意义及研究进展[J].中华肺部疾病杂志电子版，2016，9（3）：329-333.
[3] 陈筱玲，方健，聂鋆，等. 160例老年小细胞肺癌预后多因素分析[J].中国肺癌杂志，2014，17（1）：15-23.
[4] 郭成林，刘伦旭.肺癌的临床特点及诊治变化趋势[J].中华医学信息导报，2016，31（15）：15-15.
[5] 田德全，徐婷，张燕，等.血清肿瘤标志物在晚期肺癌患者一线化疗疗效评估和生存预测中的价值[J].中华检验医学杂志，2017，40（9）：693-699.
[6] 张磊，赵旭，商利明. 64排螺旋CT多期增强扫描联合血管成像对肺内肿块的诊断价值[J].中国社区医师，2016， 32（4）：123-124.
[7] 王磊，刘伟，黄晓日.老年肺癌患者CT多期增强扫描的影像学特征与特异性标记物表达相关性及联合诊断价值[J].中国老年学，2016，36（21）：5355-5357.
[8] 刘洋，贺贵福，赵义，等. SPECT/CT联合CEA、Cyfra-211、NSE诊断肺癌骨转移的价值[J].中国老年学，2015， 35（24）：7081-7083.
[9] 韩潞，江勇，谭卫林.CEA和CA19-9在结直肠癌组织中的表达及临床意义[J].实用癌症杂志，2015，30（1）：25-27.
[10] 朱琼媛，周林华，李丽莉，等.血清肿瘤标志物在结肠癌诊断中的应用价值[J].中国老年学杂志，2017，37（1）：125-127.
[11] 黄冬云，许文景，周锐，等.血清 CYFRA21-1、NSE 和 CEA 在非小细胞肺癌辅助诊断中的应用[J].中国老年学，2016，36（6）：1378-1380.
[12] Facchinetti F，Aldigeri R，Aloe R，et al. CEA serum level as early predictive marker of outcome during EGFR-TKI therapy in advanced NSCLC patients [J]. Tumor Biology，2015，36（8）：5943-5951.
[13] 陈树林，张妮，肖倩，等.血清ADAM8、CEA与血浆M2-PK三者单独及联合检测在非小细胞肺癌早期诊断中的价值[J].标记免疫分析与临床，2016，23（3）：248-251.
[14] Moss ML，Koller G，Bartsch JW，et al. A colorimetric-based amplification system for proteinases including MMP2 and ADAM8 [J]. Analytical Biochemistry，2015，484：75-81.
[15] 贾琦，刘兆国，余苏云，等.ADAM8在恶性肿瘤转移中的作用研究进展[J].中国药理学通报，2017，33（8）：1037-1040.
[16] 王雷，王顺昌，陈传波，等.乳腺癌病灶组织Her2和Adam8表达及其意义[J].武汉大学学报：医学版，2015， 36（3）：389-392.
[17] 张云，胡本顺，谈永飞，等. ADAM8蛋白在肝细胞癌的表达及其临床意义[J].中华肝胆外科杂志，2013，19（2）：116-119.
[18] Li SQ，Hu ZH，Zhu S，et al. The effect of ADAM8 on the proliferation and apoptosis of hepatocytes and hepatoma carcinoma cells [J]. Biochem Mol Toxicol，2015，29（9）：440-448.
[19] 王卿，闫凯.非小细胞肺癌组织中ADAM17的表达变化及意义[J]. 山东医药，2016，56（6）：48-49.
[20] 汪茜茜，钱章君，周炎. ADAM17在食管鳞状细胞癌组织及细胞中的表达变化及意义[J].山东医药，2015（16）：52-53. |
|
|
|
